Stevanato Group reported Q2 2026 revenue of €302 million, an 8% year-over-year increase, driven by a 9% rise in Biopharmaceutical and Diagnostic Solutions (BDS) that offset a 2% decline in Engineering. The company completed the divestiture of Balda C. Brewer, recording €12.2 million in one-time expenses. Adjusted EBITDA grew 21% to €78.7 million with a 26% margin, while adjusted diluted EPS rose to €0.14. Management updated full-year guidance, expecting revenue between €1.26 billion and €1.28 billion and adjusted EBITDA of €335 million to €345.2 million. The firm operates in the pharmaceutical packaging and drug delivery systems industry.

Stevanato Group reported Q2 2026 revenue of €302 million, an 8% increase year-over-year, driven by a 9% rise in the Biopharmaceutical and Diagnostic Solutions segment. High-value solutions (HVS) grew 16% to €136 million, representing 45% of total revenue. Adjusted EBITDA increased 21% to €78.7 million with an adjusted operating profit margin expansion to 18.0%. The company divested its California-based subsidiary Balda C. Brewer, recording a one-time loss of €12.2 million. Stevanato updated its full-year 2026 guidance, lowering the revenue midpoint slightly but maintaining organic growth expectations of 8% to 10% and adjusted diluted EPS of €0.60 to €0.62. The company operates in the pharmaceutical packaging and drug delivery systems industry.

Stevanato Group reported second quarter fiscal 2026 revenue of €302.0 million, an 8% increase year-over-year, driven by a 9% rise in its Biopharmaceutical and Diagnostic Solutions segment. The company completed the divestiture of Balda C. Brewer, Inc., recording €12.2 million in related expenses that reduced diluted earnings per share to €0.08; adjusted diluted EPS was €0.14. Gross profit margin expanded 60 basis points to 28.7%, while adjusted EBITDA margin improved 280 basis points to 26.0%. Management updated full-year guidance, projecting revenue between €1.260 billion and €1.280 billion, adjusted EBITDA of €335.0 million to €345.2 million, and adjusted diluted EPS of €0.60 to €0.62. Stevanato Group is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries.